- Home
- APLT vs ORKA Comparison
APLT vs ORKA Comparison
Compare APLT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ORKA
- Stock Information
- Founded
- APLT 2016
- ORKA 2004
- Country
- APLT United States
- ORKA United States
- Employees
- APLT N/A
- ORKA N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APLT Health Care
- ORKA Health Care
- Exchange
- APLT Nasdaq
- ORKA Nasdaq
- Market Cap
- APLT 178.6M
- ORKA 1.2B
- IPO Year
- APLT 2019
- ORKA N/A
- Fundamental
- Price
- APLT $0.24
- ORKA $27.20
- Analyst Decision
- APLT Buy
- ORKA Strong Buy
- Analyst Count
- APLT 5
- ORKA 9
- Target Price
- APLT $4.13
- ORKA $45.22
- AVG Volume (30 Days)
- APLT 6.0M
- ORKA 381.6K
- Earning Date
- APLT 11-13-2025
- ORKA 11-12-2025
- Dividend Yield
- APLT N/A
- ORKA N/A
- EPS Growth
- APLT N/A
- ORKA N/A
- EPS
- APLT N/A
- ORKA N/A
- Revenue
- APLT $1,000,000.00
- ORKA N/A
- Revenue This Year
- APLT N/A
- ORKA N/A
- Revenue Next Year
- APLT $5,935.35
- ORKA N/A
- P/E Ratio
- APLT N/A
- ORKA N/A
- Revenue Growth
- APLT N/A
- ORKA N/A
- 52 Week Low
- APLT $0.22
- ORKA $5.49
- 52 Week High
- APLT $10.48
- ORKA $29.98
- Technical
- Relative Strength Index (RSI)
- APLT 24.54
- ORKA 56.20
- Support Level
- APLT $0.75
- ORKA $25.57
- Resistance Level
- APLT $1.02
- ORKA $29.98
- Average True Range (ATR)
- APLT 0.14
- ORKA 2.19
- MACD
- APLT -0.11
- ORKA -0.43
- Stochastic Oscillator
- APLT 0.50
- ORKA 36.81
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.